Davis Polk advised the joint book-running managers in connection with a $41.4 million SEC-registered common stock offering of 1,926,250 shares of common stock of Loxo Oncology, Inc. Stifel acted as joint lead manager. The common stock is listed on the NASDAQ Global Market under the symbol “LOXO.”

Based in Stamford, Connecticut, Loxo Oncology, Inc. is a clinical-stage biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers. Loxo Oncology’s pipeline focuses on cancers that are uniquely dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

The Davis Polk corporate team included partner Bruce K. Dallas and associates Tyler P. Pender, Dongbiao Shen and Ingrid L. Perez. The tax team included partner Rachel D. Kleinberg and associate Lena X. Qiu. The intellectual property and technology team included associates Michelle Gross and Jason J. Bang. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post